Literature DB >> 11585767

Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor.

U Graeven1, U Rodeck, S Karpinski, M Jost, S Philippou, W Schmiegel.   

Abstract

Human melanoma cells express two prominent angiogenic factors, e.g., vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF/fibroblast growth factor-2). In this study, we report on the relative contribution of these two factors to in vitro and in vivo growth of a tumorigenic melanoma cell line (WM164) and nontumorigenic, immortalized melanocytes (FM516SV). Overexpression of either cytokine significantly boosted tumorigenicity of WM164 cells in immunodeficient SCID mice. Attempting to overexpress bFGF antisense sequences produced no viable clones confirming earlier reports that autocrine bFGF is obligatory to melanoma cell survival and growth. By contrast, down-regulation of endogenous VEGF production did not affect growth of WM164 cells in vitro. In vivo expansion of WM164 cells expressing VEGF antisense was delayed but not abrogated. Forced expression of either bFGF or VEGF in immortalized but nontumorigenic melanocytes did not induce sustained tumor growth in vivo highlighting that neither of the two factors is sufficient for induction of tumorigenicity in this model system. Overexpression of either cytokine in WM164 cells led to the development of atypical large vessels but not to an increase in microvessel density. Taken together our results confirm an essential autocrine role of bFGF in human melanoma and indicate a beneficial but nonessential role of VEGF in the tumorigenic phenotype of human melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

2.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

Review 4.  A new era in the treatment of melanoma: from biology to clinical practice.

Authors:  I Márquez-Rodas; S Martín Algarra; J A Avilés Izquierdo; S Custodio Cabello; M Martín
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

5.  Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.

Authors:  Oddbjørn Straume; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

6.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

7.  Melanoma biomarkers: Vox clamantis in deserto (Review).

Authors:  Mays Al-Shaer; Divya Gollapudi; Chris Papageorgio
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

Review 8.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

9.  VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.

Authors:  Ene T Raig; Natalie B Jones; Kimberly A Varker; Kristen Benniger; Michael R Go; Jennifer L Biber; Gregory B Lesinski; William E Carson
Journal:  J Interferon Cytokine Res       Date:  2008-09       Impact factor: 2.607

Review 10.  FGF/FGFR signaling in health and disease.

Authors:  Yangli Xie; Nan Su; Jing Yang; Qiaoyan Tan; Shuo Huang; Min Jin; Zhenhong Ni; Bin Zhang; Dali Zhang; Fengtao Luo; Hangang Chen; Xianding Sun; Jian Q Feng; Huabing Qi; Lin Chen
Journal:  Signal Transduct Target Ther       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.